I don't know much abotu this stuff, but my impression is it isn't looking that good. "The study found that there was a statistically significant 52% reduction in viral shedding rate for vaccine recipients, when the post-vaccine period was compared with pre-vaccine, and a non-significant 31% reduction in shedding was observed over the course of the study for the subjects receiving placebo. When the extent of reduction in shedding was compared between the vaccine and the placebo groups, however, the reduction associated with vaccine was non-significant."
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus Releases Results of HSV-2 Phase IIa Study
AVR
anteris technologies global corp.
Add to My Watchlist
5.16%
!
$5.91

Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-2
-
- There are more pages in this discussion • 231 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.91 |
Change
0.290(5.16%) |
Mkt cap ! $91.59M |
Open | High | Low | Value | Volume |
$5.79 | $6.19 | $5.79 | $17.15K | 2.906K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 38 | $5.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.10 | 170 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 38 | 5.900 |
1 | 1000 | 5.850 |
1 | 104 | 5.800 |
2 | 3500 | 5.600 |
1 | 3045 | 5.510 |
Price($) | Vol. | No. |
---|---|---|
6.100 | 170 | 1 |
6.200 | 500 | 1 |
6.300 | 100 | 1 |
6.400 | 450 | 2 |
6.550 | 1092 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online